title: A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers.
abstract: Currently there are three targeted therapies approved for the treatment of colorectal cancers. These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations of cutaneous toxicity that result from these agents to effectively manage symptoms and prevent premature discontinuation of anticancer treatment.
authors.affiliation: Washington University of St. Louis School of Medicine, St. Louis, Missouri, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Urban
authors.forename: Milan J
authors.initials: MJ
authors.lastname: Anadkat
keywords: Cetuximab; panitumumab; regorafenib